Literature DB >> 18593912

Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance.

Catherine M Shachaf1, Andrew J Gentles, Sailaja Elchuri, Debashis Sahoo, Yoav Soen, Orr Sharpe, Omar D Perez, Maria Chang, Dennis Mitchel, William H Robinson, David Dill, Garry P Nolan, Sylvia K Plevritis, Dean W Felsher.   

Abstract

MYC overexpression has been implicated in the pathogenesis of most types of human cancers. MYC is likely to contribute to tumorigenesis by its effects on global gene expression. Previously, we have shown that the loss of MYC overexpression is sufficient to reverse tumorigenesis. Here, we show that there is a precise threshold level of MYC expression required for maintaining the tumor phenotype, whereupon there is a switch from a gene expression program of proliferation to a state of proliferative arrest and apoptosis. Oligonucleotide microarray analysis and quantitative PCR were used to identify changes in expression in 3,921 genes, of which 2,348 were down-regulated and 1,573 were up-regulated. Critical changes in gene expression occurred at or near the MYC threshold, including genes implicated in the regulation of the G(1)-S and G(2)-M cell cycle checkpoints and death receptor/apoptosis signaling. Using two-dimensional protein analysis followed by mass spectrometry, phospho-flow fluorescence-activated cell sorting, and antibody arrays, we also identified changes at the protein level that contributed to MYC-dependent tumor regression. Proteins involved in mRNA translation decreased below threshold levels of MYC. Thus, at the MYC threshold, there is a loss of its ability to maintain tumorigenesis, with associated shifts in gene and protein expression that reestablish cell cycle checkpoints, halt protein translation, and promote apoptosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18593912      PMCID: PMC4191850          DOI: 10.1158/0008-5472.CAN-07-6192

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

1.  Analysis of gene expression during myc oncogene-induced lymphomagenesis in the bursa of Fabricius.

Authors:  P E Neiman; A Ruddell; C Jasoni; G Loring; S J Thomas; K A Brandvold; J Burnside; J Delrow
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

2.  Myc-binding-site recognition in the human genome is determined by chromatin context.

Authors:  Ernesto Guccione; Francesca Martinato; Giacomo Finocchiaro; Lucilla Luzi; Laura Tizzoni; Valentina Dall' Olio; Giuseppe Zardo; Clara Nervi; Loris Bernard; Bruno Amati
Journal:  Nat Cell Biol       Date:  2006-06-11       Impact factor: 28.824

Review 3.  Transcriptional regulation and transformation by Myc proteins.

Authors:  Sovana Adhikary; Martin Eilers
Journal:  Nat Rev Mol Cell Biol       Date:  2005-08       Impact factor: 94.444

4.  Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes.

Authors:  Antje Menssen; Heiko Hermeking
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-30       Impact factor: 11.205

5.  Reversible tumorigenesis by MYC in hematopoietic lineages.

Authors:  D W Felsher; J M Bishop
Journal:  Mol Cell       Date:  1999-08       Impact factor: 17.970

6.  Development of a real-time reverse transcription polymerase chain reaction assay for c-myc expression that allows the identification of a subset of c-myc+ diffuse large B-cell lymphoma.

Authors:  Ana-Isabel Sáez; María-Jesús Artiga; Cristina Romero; Sandra Rodríguez; Juan-Cruz Cigudosa; Alberto Pérez-Rosado; Isabel Fernández; Margarita Sánchez-Beato; Esther Sánchez; Manuela Mollejo; Miguel A Piris
Journal:  Lab Invest       Date:  2003-02       Impact factor: 5.662

7.  c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations.

Authors:  C M D'Cruz; E J Gunther; R B Boxer; J L Hartman; L Sintasath; S E Moody; J D Cox; S I Ha; G K Belka; A Golant; R D Cardiff; L A Chodosh
Journal:  Nat Med       Date:  2001-02       Impact factor: 53.440

8.  Reversible kinetic analysis of Myc targets in vivo provides novel insights into Myc-mediated tumorigenesis.

Authors:  Elizabeth R Lawlor; Laura Soucek; Lamorna Brown-Swigart; Ksenya Shchors; C Uli Bialucha; Gerard I Evan
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

9.  A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells.

Authors:  Zirong Li; Sara Van Calcar; Chunxu Qu; Webster K Cavenee; Michael Q Zhang; Bing Ren
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-13       Impact factor: 11.205

10.  An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets.

Authors:  Karen I Zeller; Anil G Jegga; Bruce J Aronow; Kathryn A O'Donnell; Chi V Dang
Journal:  Genome Biol       Date:  2003-09-11       Impact factor: 13.583

View more
  49 in total

Review 1.  c-Myc induction of programmed cell death may contribute to carcinogenesis: a perspective inspired by several concepts of chemical carcinogenesis.

Authors:  Chenguang Wang; Yanhong Tai; Michael P Lisanti; D Joshua Liao
Journal:  Cancer Biol Ther       Date:  2011-04-01       Impact factor: 4.742

2.  Demonstration that drug-targeted down-regulation of MYC in non-Hodgkins lymphoma is directly mediated through the promoter G-quadruplex.

Authors:  Robert V Brown; Forest L Danford; Vijay Gokhale; Laurence H Hurley; Tracy A Brooks
Journal:  J Biol Chem       Date:  2011-09-28       Impact factor: 5.157

3.  p27Kip1 mediates addiction of ovarian cancer cells to MYCC (c-MYC) and their dependence on MYC paralogs.

Authors:  Tulsiram Prathapam; Alexey Aleshin; Yinghui Guan; Joe W Gray; G Steven Martin
Journal:  J Biol Chem       Date:  2010-07-20       Impact factor: 5.157

4.  EGFR signals downregulate tumor suppressors miR-143 and miR-145 in Western diet-promoted murine colon cancer: role of G1 regulators.

Authors:  Hongyan Zhu; Urszula Dougherty; Victoria Robinson; Reba Mustafi; Joel Pekow; Sonia Kupfer; Yan Chun Li; John Hart; Kathleen Goss; Alessandro Fichera; Loren Joseph; Marc Bissonnette
Journal:  Mol Cancer Res       Date:  2011-06-08       Impact factor: 5.852

5.  Methods of Expression, Purification, and Preparation of the c-Myc b-HLH-LZ for Its Biophysical Characterization.

Authors:  Patrick Delattre; Martin Montagne; Pierre Lavigne
Journal:  Methods Mol Biol       Date:  2021

6.  MYC activates stem-like cell potential in hepatocarcinoma by a p53-dependent mechanism.

Authors:  Hirofumi Akita; Jens U Marquardt; Marian E Durkin; Mitsuteru Kitade; Daekwan Seo; Elizabeth A Conner; Jesper B Andersen; Valentina M Factor; Snorri S Thorgeirsson
Journal:  Cancer Res       Date:  2014-09-04       Impact factor: 12.701

Review 7.  The role of supercoiling in transcriptional control of MYC and its importance in molecular therapeutics.

Authors:  Tracy A Brooks; Laurence H Hurley
Journal:  Nat Rev Cancer       Date:  2009-11-12       Impact factor: 60.716

8.  Integrated network analysis of transcriptomic and proteomic data in psoriasis.

Authors:  Eleonora Piruzian; Sergey Bruskin; Alex Ishkin; Rustam Abdeev; Sergey Moshkovskii; Stanislav Melnik; Yuri Nikolsky; Tatiana Nikolskaya
Journal:  BMC Syst Biol       Date:  2010-04-08

Review 9.  Reactive oxygen species-dependent signaling regulates cancer.

Authors:  Frank Weinberg; Navdeep S Chandel
Journal:  Cell Mol Life Sci       Date:  2009-07-24       Impact factor: 9.261

10.  PrognoScan: a new database for meta-analysis of the prognostic value of genes.

Authors:  Hideaki Mizuno; Kunio Kitada; Kenta Nakai; Akinori Sarai
Journal:  BMC Med Genomics       Date:  2009-04-24       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.